PRECICE® ADK Assay Kit provides a convenient, high throughput compatible and non-radioactive assay for in vitro measurement of ADK activity and for Drug Discovery of novel ADK inhibitors. Novel tool for Drug Discovery, this kit allows HTS search of novel ADK inhibitors.
Adenosine kinase uses ATP as the phosphate donor. It transfers the terminal phosphate group of ATP to a substrate, producing ADP as a by-product. The assay is based on the use of inosine as a surrogate ADK substrate and a coupled reaction involving a highly active IMPDH (Inosine Monophosphate Dehydrogenase) for a direct measurement of the inosine monophosphate (IMP) formed by ADK. In the presence of inosine and ATP, ADK catalyses the phosphorylation of inosine to form IMP and ADP. IMP is then immediately oxidized to XMP by a highly active IMPDH in the presence of NAD, leading to NADH2 formation.
| #REF | SIZE | PRICE | |
|---|---|---|---|
| #K0507-01.01 | 1 plate (96 assays) | € 420.00 | Inquiry |
| #K0507-01.05 | 5 plates (5 x 96 assays) | € 1,680.00 | Inquiry |
Pricing updated December 25th, 2013.
Kit is provided in stable lyophilized form and shipped without dry ice
Download In vitro ADK asssay protocol (User manual)
For rapid analysis of in vitro phosphorylation of novel nucleoside analogs for human adenosine kinase see our PRECICE® ADK Phosphorylation Assay Kit.
Adenosine kinase is a ubiquitous enzyme regulating intra- and extracellular concentrations of adenosine (AR), an important modulator of central nervous system functions and a signal molecule involved in hypoxia, inflammation and nociception. Together with adenosine demainase, adenosine kinase regulates intra- and extracellular cellular adenosine concentration. Inhibition of adenosine kinase results in selective increase of local adenosine concentrations and reduced seizure susceptibility and nociception in vivo(3). ADK dysfunction is involved in several pathologies, including diabetes(13), epilepsy(6), and cancer. Consequently, ADK emerges as a rational therapeutic target, and adenosine-regulating drugs have been extensively tested (1) as new analgesic and anti-inflammatory agents(4) to treat schizophrenia(7) or to limit brain injury after an ischemic stroke(8).
The use of PRECICE® ADK Screening Assay Kit for the screening of ADK inhibitors and IC50 measurements was validated with compound A-134974, a known ADK inhibitor (Sigma-Aldrich, under license from Abbott Laboratories). Z'-Factor was calculated from 44 negative (no ADK inhibition) and positive (inhibition of ADK with 500nM A-134974) and measured as 0.68, which is an excellent level of performance for a screening assay
